Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus

Objective: to study the safety and efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE).

Patients and methods. The study included 75 patients with definite diagnosis of SLE at the age of 19–68 years, 10 (13%) of them had high SLE activity, 18 (24%) – moderate, 42 (56%) – low, in 5 (7%) patients the disease was in remission. PPV-23 was injected subcutaneously in a single dose of 0.5 ml. In 60 patients the follow-up period was ≥12 months, in 15 – from 2 to 6 months. Patients were examined before and 1, 3 and 12 months after immunization.

Results and discussion. In 38 (50.7%) patients, standard local vaccination reactions of mild and moderate severity were noted, in 1 (1.3%) – a general reaction of mild severity, in 2 (2.7%) – mild diarrhea during 1 day, in 1 (1.3%) – a hyperergic reaction of the Artyus phenomenon type, the symptoms were relieved within 7 days. During 12 months of follow-up, neither exacerbations of SLE, reliably associated with vaccination, nor new autoimmune phenomena, were detected. After 1 year of observation, the number of responders to vaccination was 58%, non-responders – 42%. The duration and activity of the disease, age over 50 years, glucocorticoid therapy > 10 mg per day, did not significantly affect the vaccine response. There was a decrease in the immune response in patients on biologic DMARDs (bDMARDs) therapy compared to patients without such treatment (43 and 68% of cases, respectively), p=0.058. There was no difference between rituximab and belimumab treated subjects. There was a tendency for the prevalence of vaccination responses among patients, who received bDMARDs <1 year before immunization, as well as among patients in whom this therapy was initiated after the administration of PPV-23. There was a positive trend in decrease of pneumonia, acute and exacerbations of chronic bronchitis episodes and sinusitis.

Conclusion. Sufficient immunogenicity, good tolerability and clinical efficacy of PPV-23 in patients with SLE, including those who received combined immunosuppressive therapy, have been shown. The use of bDMARDs reduces the number of patients with a vaccine response. The number of responders to vaccination increases when immunization is carried out before the initiation of therapy with bDMARDs or when this therapy is initiated <1 year before immunization. Further long-term prospective studies in large patient cohorts are required.

1. Chuchalin AG, Briko NI, Avdeev SN, et al. Federal clinical guidelines for the vaccination of pneumococcal infection in adults. Pul'monologiya. 2019;29(1):19-34. (In Russ.).

2. Tatochenko VK, Ozeretskovskii NA. Immunoprofilaktika-2018. Spravochnik. 13-e izd. [Immunoprophylaxis-2018. Guide. 13th ed.]. Moscow: Borges; 2018.

3. Mykietiuk A, Carratala J, Dominguez A, et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006 Jul;25(7):457-62. doi: 10.1007/s10096-006-0161-8.

4. Fisman D, Abrutyn E, Spaude KA, et al. Prior pneumoccoccal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006 Apr 15;42(8):1093-101. doi: 10.1086/501354. Epub 2006 Mar 13.

5. Johnstone J, Marrie T, Eurich D, et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007 Oct 8; 167(18):1938-43. doi: 10.1001/archinte.167.18.1938.

6. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):309-18. doi: 10.1093/cid/cit816.

7. Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid- induced side effects: A comprehensive review. Infectious complications and vaccination recommendations. J Am Acad Dermatol. 2017 Feb;76(2):191-8. doi: 10.1016/j.jaad.2016.02.1240.

8. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-22. doi: 10.1136/ard.2010.137216. Epub 2010 Dec 3.

9. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.

10. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug; 64(8):2677-86. doi: 10.1002/art.34473.

11. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.

12. Kozlov RS. Modern possibilities of specific prevention of pneumococcal infections. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2002;4(1):61-9. (In Russ.).

13. Nguyen M, Lindegaard H, Hendricks O, Friis-Moller N. Factors associatedwith influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017 Nov;46(6):446-53. doi: 10.1080/03009742.2016.1242774. Epub 2017 Feb 1.

14. Loubet P, Kerneis S, Groh M, et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015 Jul 17;33(31):3703-8. doi: 10.1016/j.vaccine.2015.06.012. Epub 2015 Jun 11.

15. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016 Aug 4;17:322. doi: 10.1186/s12891-016-1187-4.

16. Naumtseva MS, Belov BS, Aleksandrova EN, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: Results of a two-year follow-up study. Nauchno-Prakticheskaya Revmtologiya. 2016;54(6):674-80 (In Russ.).

17. Bukhanova D, Sergeeva M, Belov B, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in ra patients: results of a 4-year follow up study. Ann Rheum Dis. 2018;77(Suppl 2):1060. doi: 10.1136/annrheumdis-2018-eular.1586

18. Bukhanova D, Belov B, Tarasova G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis. 2019;78(Suppl 2): 336. doi: 10.1136/annrheumdis-2019-eular.3173

19. Tarasova G, Belov B, Bukhanova D, et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis. 2019; 78(Suppl 2):785-6. doi: 10.1136/annrheumdis-2019-eular.3646

20. Puges M, Biscay P, Barnetche T, et al. Immunogenicity and impact on diseaseactivity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and metaanalysis. Rheumatology (Oxford). 2016 Sep;55(9): 1664-72. doi: 10.1093/rheumatology/kew211.Epub 2016 May 9.

21. Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016 Dec 2;6:37817. doi: 10.1038/srep37817.

22. Bü hler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015 Jul 28;145:w14159. doi: 10.4414/smw.2015.14159. eCollection 2015.

23. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002 Jan 15;34(2):147-53. doi: 10.1086/338043. Epub 2001 Dec 4.

24. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26. doi: 10.1002/acr.22246.

25. Crnkic Kapetanovic M, Saxne T, Jö nsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013 Oct 30;15(5):R171. doi: 10.1186/ar4358.

26. Binder M, Otto F, Mertelsmann R, et al. The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. doi: 10.1182/blood-2006-04-014639. Epub 2006 May 16.